再生障碍性贫血雄激素治疗选择及研究现状  

The choice and research status of androgen in aplastic anemia treatment

作　　者：周琦浩 吴迪炯[2] 叶宝东[2] 周郁鸿[2] 

机构地区：[1]浙江中医药大学第一临床医学院,杭州310053 [2]浙江省中医院血液科

出　　处：《临床血液学杂志》2015年第1期87-89,共3页Journal of Clinical Hematology

基　　金：国家中医药管理局中医药行业科研专项(No:201107001);浙江省中医药重大疾病科技创新平台科研专项(No:2009ZDJB01)

摘　　要：再生障碍性贫血（aplastic anemia,AA）简称再障,是一种获得性骨髓衰竭性疾病,以全血细胞减少以及所致的贫血、感染和出血等临床表现为特征。目前通常将AA分为非重型再障（NSAA）、重型再障（SAA）、极重型再障（VSAA）〔1-3〕。目前的治疗策略主要是造血干细胞移植（HSCT）和免疫抑制治疗（IST）,通常以抗胸腺细胞球蛋白（ATG）和环孢素A（CsA）作为一线治疗〔1〕。Aplastic anemia（AA）is a rare disease characterized by bone marrow aplasia and pancytopenia.Immunosuppressive therapy is the standard treatment for AA patients who are not eligible for allogeneic hematopoietic stem cell transplantation.But its high price and other factors make the majority of patients cannot afford it.Before ATG＋CsA were introduced into the treatment of AA,androgens were the usual therapy.According to the widely researches on androgens in AA in the past 20 years,it detailed the mechanism,effect and selection of androgens in AA treatment.It revealed that androgens continue to be a treatment option in AA,especially for non-severe AA patients and female patients,as well as some patients with relapsed or refractory AA.

关 键 词：贫血 再生障碍性 雄激素 治疗 

分 类 号：R556.5[医药卫生—血液循环系统疾病]